ATE253377T1 - Verfahren zur steigerung der immunogenizität, erhaltenes produkt und arzneimittel - Google Patents

Verfahren zur steigerung der immunogenizität, erhaltenes produkt und arzneimittel

Info

Publication number
ATE253377T1
ATE253377T1 AT95929918T AT95929918T ATE253377T1 AT E253377 T1 ATE253377 T1 AT E253377T1 AT 95929918 T AT95929918 T AT 95929918T AT 95929918 T AT95929918 T AT 95929918T AT E253377 T1 ATE253377 T1 AT E253377T1
Authority
AT
Austria
Prior art keywords
product
increase immunogenicity
antigen
medicinal
relates
Prior art date
Application number
AT95929918T
Other languages
English (en)
Inventor
Didier Betbeder
Christian Davrinche
Jean-Luc Davignon
Eric Prieur
Original Assignee
Biovector Therapeutics Sa
Inst Nat Sante Rech Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biovector Therapeutics Sa, Inst Nat Sante Rech Med filed Critical Biovector Therapeutics Sa
Application granted granted Critical
Publication of ATE253377T1 publication Critical patent/ATE253377T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT95929918T 1994-08-31 1995-08-31 Verfahren zur steigerung der immunogenizität, erhaltenes produkt und arzneimittel ATE253377T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9410479A FR2723849B1 (fr) 1994-08-31 1994-08-31 Procede pour augmenter l'immunogenicite, produit obtenu et composition pharmaceutique
PCT/FR1995/001138 WO1996006638A1 (fr) 1994-08-31 1995-08-31 Procede pour augmenter l'immunogenicite, produit obtenu et composition pharmaceutique

Publications (1)

Publication Number Publication Date
ATE253377T1 true ATE253377T1 (de) 2003-11-15

Family

ID=9466603

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95929918T ATE253377T1 (de) 1994-08-31 1995-08-31 Verfahren zur steigerung der immunogenizität, erhaltenes produkt und arzneimittel

Country Status (12)

Country Link
US (1) US6342226B1 (de)
EP (1) EP0814835B1 (de)
JP (1) JPH10509690A (de)
KR (1) KR970705411A (de)
AT (1) ATE253377T1 (de)
AU (1) AU704633B2 (de)
CA (1) CA2198479A1 (de)
DE (1) DE69532088T2 (de)
DK (1) DK0814835T3 (de)
ES (1) ES2210310T3 (de)
FR (1) FR2723849B1 (de)
WO (1) WO1996006638A1 (de)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6613332B1 (en) 1991-06-21 2003-09-02 The University Of Cincinnati Oral administration of therapeutic proteins
FR2723849B1 (fr) 1994-08-31 1997-04-11 Biovector Therapeutics Sa Procede pour augmenter l'immunogenicite, produit obtenu et composition pharmaceutique
FR2757169B1 (fr) * 1996-12-13 1999-03-05 Inst Nat Sante Rech Med Proteine de fusion comportant tout ou partie de la proteine pp65 de cmv humain, utile notamment dans la preparation d'un vaccin
US6096291A (en) * 1996-12-27 2000-08-01 Biovector Therapeutics, S.A. Mucosal administration of substances to mammals
US7189753B1 (en) 1997-11-06 2007-03-13 Cady Roger K Preemptive prophylaxis of migraine
US6328967B1 (en) 1998-03-12 2001-12-11 Allergenics, Inc. Delivery system to modulate immune response
US20020147143A1 (en) 1998-03-18 2002-10-10 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US20040009535A1 (en) 1998-11-27 2004-01-15 Celltech R&D, Inc. Compositions and methods for increasing bone mineralization
US6741664B1 (en) * 1999-02-05 2004-05-25 Broadcom Corporation Low-latency high-speed trellis decoder
MXPA01009962A (es) 1999-04-02 2002-08-20 Corixa Corp Compuestos y metodos para terapia y diagnostico de cancer de pulmon.
CN1254541C (zh) 2000-02-23 2006-05-03 史密丝克莱恩比彻姆生物有限公司 新化合物
US20040002068A1 (en) 2000-03-01 2004-01-01 Corixa Corporation Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
DE60133190T2 (de) 2000-04-21 2009-04-02 CORIXA CORP., Wilmington Verbindungen und verfahren zur behandlung und diagnose von chlamydia-infektionen
DE60139963D1 (de) 2000-06-20 2009-10-29 Corixa Corp Fusionsproteine aus mycobakterium tuberculosis
EP1319069B1 (de) 2000-06-28 2008-05-21 Corixa Corporation Zusammensetzungen und verfahren für therapie und diagnose von lungenkrebs
FR2815870A1 (fr) * 2000-10-27 2002-05-03 Biovector Therapeutics Utilisation de particules hydrophiles associees a des antigenes identiques ou differents pour la preparation de compositions de vaccin
CA2446788A1 (en) 2001-05-09 2002-11-14 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
EP1581119B1 (de) 2001-12-17 2013-01-30 Corixa Corporation Zusammensetzungen und verfahren zur behandlung und diagnose von entzündlicher darmerkrankung
US20080233181A1 (en) * 2002-04-12 2008-09-25 Nagy Jon O Nanoparticle adjuvants for sub-unit vaccines
US7285289B2 (en) * 2002-04-12 2007-10-23 Nagy Jon O Nanoparticle vaccines
DK1589934T3 (en) 2003-01-06 2015-12-21 Corixa Corp Certain AMINOAL COOLER GLUCOSAMINIDE PHOSPHATE COMPOUNDS AND APPLICATION
US7960522B2 (en) 2003-01-06 2011-06-14 Corixa Corporation Certain aminoalkyl glucosaminide phosphate compounds and their use
US7381409B2 (en) 2003-06-16 2008-06-03 Celltech R&D, Inc. Antibodies specific for sclerostin and methods of screening and use therefor
EP1651666B1 (de) * 2003-07-11 2009-05-27 Alphavax, Inc. Cytomegalovirusimpfstoffe, die auf dem alphavirus basieren
EP2497831B1 (de) 2004-05-25 2014-07-16 Oregon Health and Science University TB-Impfung unter Verwendung von Impfvektoren auf HCMV-Basis
EP1797173B1 (de) 2004-10-08 2014-05-14 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Modulierung der replikationsrate durch verwendung von seltener verwendeten synonymen kodons
BRPI0609547A2 (pt) 2005-03-31 2011-10-18 Glaxosmithkline Biolog Sa composição, uso de uma composição, método para o tratamento ou prevenção de infecção por chlamydia, uso de uma ou mais proteìnas de chlamydia, de fragmentos imunogênicos das mesmas ou de polinucleotìdeos codificando os mesmos, método para o tratamento ou prevenção de infecção por chlamydia, e, método para a determinação prévia de infecção por chlamydia em um indivìduo
SI2457926T1 (sl) 2005-04-29 2015-01-30 Glaxosmithkline Biologicals S.A. Nov postopek za preprečevanje ali zdravljenje infekcije z M. tuberculosis
US9259463B2 (en) 2006-01-16 2016-02-16 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Chlamydia vaccine
US7375084B2 (en) 2006-03-07 2008-05-20 Baxter International Inc. Highly phosphorylated and sulfated recombinant factor IX
CA2648718A1 (en) 2006-04-07 2007-10-18 The Research Foundation Of State University Of New York Transcobalamin receptor polypeptides, nucleic acids, and modulators thereof, and related methods of use in modulating cell growth and treating cancer and cobalamin deficiency
EP1897538A1 (de) * 2006-08-23 2008-03-12 Stallergenes Sa Formulierungen für Antigen-spezifische Toleranzinduktion
DK2183368T3 (en) 2007-06-21 2016-09-05 Alphavax Inc PROMOTER-FREE CASES FOR EXPRESSION OF ALPHAVIRUS STRUCTURE PROTEINS
US8619257B2 (en) 2007-12-13 2013-12-31 Kimberley-Clark Worldwide, Inc. Recombinant bacteriophage for detection of nosocomial infection
AU2008342260B2 (en) 2007-12-27 2013-10-17 Baxter Healthcare S.A. Chemically modified Factor IX
JP2011525477A (ja) 2008-03-04 2011-09-22 リクイディア・テクノロジーズ・インコーポレーテッド 免疫調節剤粒子および処置方法
AU2009236585B2 (en) 2008-04-18 2013-03-07 Vaxinnate Corporation Deletion mutants of flagellin and methods of use
EP2477652B1 (de) 2009-09-16 2015-04-15 Vaxart, Inc. Immunisierungsstrategie zur verhinderung von h1n1-infektionen
CN103608030A (zh) 2011-06-21 2014-02-26 昂科发克特公司 用于治疗和诊断癌症的组合物和方法
US10208086B2 (en) 2011-11-11 2019-02-19 Fred Hutchinson Cancer Research Center Cyclin A1-targeted T-cell immunotherapy for cancer
GB201710973D0 (en) 2017-07-07 2017-08-23 Avacta Life Sciences Ltd Scaffold proteins
JP7448954B2 (ja) 2018-02-21 2024-03-13 ザ ユニバーシティー オブ モンタナ ジアリールトレハロース化合物及びその使用
US11572381B2 (en) 2018-03-02 2023-02-07 The University Of Montana Immunogenic trehalose compounds and uses thereof
KR20220018503A (ko) 2019-05-23 2022-02-15 더 유니버시티 오브 몬타나 Tlr 수용체 리간드에 기반한 백신 애주번트
JP7765379B2 (ja) 2019-08-12 2025-11-06 ピュリノミア バイオテック， インコーポレイテッド Ｃｄ３９発現細胞のａｄｃｃ標的化を介してｔ細胞媒介性免疫応答を促進及び増強するための方法及び組成物
TW202128775A (zh) 2019-10-16 2021-08-01 英商阿法克塔生命科學有限公司 PD-L1抑制劑-TGFβ抑制劑雙特異性藥物部分
GB202101299D0 (en) 2020-06-09 2021-03-17 Avacta Life Sciences Ltd Diagnostic polypetides and methods
FR3112284B1 (fr) * 2020-07-10 2024-02-09 Vaxinano Procede de preparation d’une composition vaccinale a partir d’antigenes lyophilises
WO2022234003A1 (en) 2021-05-07 2022-11-10 Avacta Life Sciences Limited Cd33 binding polypeptides with stefin a protein
TW202334196A (zh) 2021-10-07 2023-09-01 英商阿法克塔生命科學有限公司 Pd-l1結合多肽
EP4412711A1 (de) 2021-10-07 2024-08-14 Avacta Life Sciences Limited Serumhalbwertszeiterweiterte pd-l1-bindende polypeptide
WO2023153876A1 (ko) 2022-02-10 2023-08-17 주식회사 아피셀테라퓨틱스 Cd40l에 특이적으로 결합하는 스테핀 a 단백질 변이체 및 이의 용도
WO2023212483A1 (en) 2022-04-29 2023-11-02 Purinomia Biotech, Inc. Methods and compositions for treating eosinophil driven diseases and disorders
WO2023218243A1 (en) 2022-05-12 2023-11-16 Avacta Life Sciences Limited Lag-3/pd-l1 binding fusion proteins
EP4656648A1 (de) 2024-05-31 2025-12-03 Consejo Superior De Investigaciones Científicas Immunmodulatorische thioharnstoff- und harnstoffkohlenhydratverbindungen und verwendungen davon

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6090406A (en) * 1984-04-12 2000-07-18 The Liposome Company, Inc. Potentiation of immune responses with liposomal adjuvants
US4925678A (en) 1987-04-01 1990-05-15 Ranney David F Endothelial envelopment drug carriers
FR2631826B1 (fr) 1988-05-27 1992-06-19 Centre Nat Rech Scient Vecteur particulaire utile notamment pour le transport de molecules a activite biologique et procede pour sa preparation
FR2702160B1 (fr) * 1993-03-02 1995-06-02 Biovecteurs As Vecteurs particulaires synthétiques et procédé de préparation.
FR2704145B1 (fr) * 1993-04-21 1995-07-21 Pasteur Institut Vecteur particulaire et composition pharmaceutique le contenant.
FR2723849B1 (fr) 1994-08-31 1997-04-11 Biovector Therapeutics Sa Procede pour augmenter l'immunogenicite, produit obtenu et composition pharmaceutique

Also Published As

Publication number Publication date
WO1996006638A1 (fr) 1996-03-07
DE69532088T2 (de) 2004-09-02
AU704633B2 (en) 1999-04-29
US6342226B1 (en) 2002-01-29
AU3349095A (en) 1996-03-22
CA2198479A1 (fr) 1996-03-07
EP0814835B1 (de) 2003-11-05
FR2723849B1 (fr) 1997-04-11
ES2210310T3 (es) 2004-07-01
KR970705411A (ko) 1997-10-09
DK0814835T3 (da) 2004-03-08
JPH10509690A (ja) 1998-09-22
DE69532088D1 (de) 2003-12-11
FR2723849A1 (fr) 1996-03-01
EP0814835A1 (de) 1998-01-07

Similar Documents

Publication Publication Date Title
DE69532088D1 (de) Verfahren zur steigerung der immunogenizität, erhaltenes produkt und arzneimittel
DZ2314A1 (fr) Formulation pour administration par voie orale à libération immédiate retardée et procédé pour sa préparation.
ATE77741T1 (de) Insbesondere zum tragen von biologisch aktiven molekuelen geeignetes teilchenfoermiges vektorsystem und verfahren zu seiner herstellung.
ES2188784T3 (es) Composiciones desodorantes antitranspirantes.
MA26530A1 (fr) Derives d'acides aryloxyarylsulfonylaminohydroxamiques; procede pour leur preparation et compostions pharmaceutiques les contenant.
ATE218359T1 (de) Neue zubereitungsformen des cyclosporins zur oralen applikation mit einfacher zusammensetzung und hoher bioverfügbarkeit und verfahren zu deren herstellung
DZ2523A1 (fr) Formulations pharmaceutiques contenant du voriconazole et procédé pour leur préparation.
DE3750363D1 (de) Verfahren zur Fraktionierung einer Fettsäuremischung.
ATE214596T1 (de) Feste zusammensetzungen mit einem nicht-amorphem wirkstoff und polyäthylenoxyd
DE69121502D1 (de) Prozess zur darstellung von aspartam aus einem diketopiperazin sowie neue zwischenprodukte und derivate dafür
GR920300128T1 (en) Method for preparing a lipoprotein modified by the incorporation of a lipophilic active substance
DE2920890A1 (de) Neue physiologisch aktive derivate des esterastins sowie verfahren zur herstellung derselben
DE59611383D1 (de) Darreichungsform zur applikation von pharmazeutischen wirkstoffen und hilfsstoffen und verfahren zur herstellung derselben
ATE111455T1 (de) 3-substituierte 1,2,3,4-oxatriazol-5- iminderivate, verfahren zur herstellung sowie diese enthaltende arzneimittel.
DE59505146D1 (de) Liposomen enthaltend darin verkapselte proteine, verfahren zu ihrer herstellung sowie diese liposomen enthaltende pharmazeutische und kosmetische zubereitungen
PT74119A (de) Verfahren zur herstellung von neuen estern der 7beta-<2-(2- -amino-4-thiazolyl)-2-(syn)-methoxyiminoacetamido>-3-cephem-4- -carbonsaeure und pharmazeutische praeparate die solche verbin-dungen enthalten
ATE338819T1 (de) Antigenes protein aus malassezia
AT399504B (de) Neue aminopropoxyimino-cycloalkanderivate, deren herstellung, arzneimittel, die diese verbindungen als wirkstoff enthalten sowie verfahren zur herstellung derselben
DE69621747D1 (de) Verfahren zur Herstellung von Benzylacetat und Benzylalkohol
ATE189677T1 (de) Verfahren zur herstellung von furosemide
DE68914175D1 (de) Parfümgrundzusammenstellung enthaltendes 2-cyclohexylpropanal und Verfahren zur Herstellung dieser Verbindung.
DE69600338D1 (de) Verfahren zur Herstellung von Naphthalin-2,6-dicarbonsäure und ihrem Ester
ZA791844B (en) Process for the preparation of sulphur-containing n-benzyl amino acids, such compounds in optically active form, and pharmaceutical compositions thereof
DE60100080D1 (de) Derivate von Aryl- oder Heteroaryl-Quinolinylphosphonsäuren, Verfahren zu ihrer Herstellung und sie enthaltende Arzneimittel
ES2131325T3 (es) Sustitutos de trigliceridos estables para usar en controles o calibradores de ensayos quimicos clinicos y procedimientos para su preparacion.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0814835

Country of ref document: EP

REN Ceased due to non-payment of the annual fee